The increased understanding of the human immune system and the emergence of immune modulation techniques has led to the development of a new era of immunotherapy in the management of lung cancer. In recent years, immunotherapy has been established as the fourth pillar in the management of cancer, which targets the cancer cell by augmenting an immune response against it. The extensive research and development activities by researchers has led to the development of several immunotherapeutic approaches including checkpoint inhibitors, vaccines, therapeutic antibodies, immunomodulatory, and others.
At present, various therapeutic antibodies and immune checkpoint inhibitors have gained approval for the management of lung cancer. Immune checkpoint inhibitor therapy targeting the cytotoxic T-lymphocyte-associated antigen (CTLA-4) and programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) pathway have gained entry into the market. In addition to this, monoclonal antibodies including Cyramza, Avastin, and Portaza have also been approved for the management of various subtypes of lung cancer. Recently in 2021, a novel bispecific antibody Rybrevant (Amivantamab) was granted approval by US FDA. Rybrevant is an EGF and MET-directed bispecific antibody, developed by Janssen Pharmaceutical which is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EFGR) exon 20 insertion mutations. Clinical trials have demonstrated that the novel drug has shown enhanced efficacy in comparison to previously approved MET and EFGR inhibitors.
The huge clinical success of antibody therapeutics in the management of lung cancer has gained considerable momentum in the global market. In recent times, more enhance counterparts; trispecific antibodies which have the ability to bind to three different antigens simultaneously have also entered clinical development. HPN328 developed by Harpoon Therapeutics is TriTAC that binds to human and non-human primate DLL3, CD3ε, and albumin with similar affinities. US FDA has granted orphan drug designation for HPN328 for the treatment of small-cell lung cancer (SCLC). A Phase 1/2 clinical trial is currently ongoing for HPN328 in the SCLC patient population.
The global lung cancer antibody therapeutics market is highly consolidated with several key players investing in research and development. Several pharmaceutical giants have also adopted strategic alliances including partnerships, joint ventures, or collaborations to evaluate novel antibody therapeutics as monotherapy or in combinational therapy. Recently, Akeso has entered into collaboration with Shenzhen Chipscreen Biosciences to evaluate the combination of PD-1/CTLA-4 bi-specific antibody Cadonilimab in combination with Chiauranib for the treatment of first-line platinum-based chemotherapy in combination with PD-L1 inhibitor treatment regimen for extensive-stage small cell lung cancer (ES-SCLC).
As per our report findings, the global lung cancer antibody therapeutics market is expected to surpass US$ 10 Billion by 2028. The rise in the incidence of various lung cancer conditions, increase in popularity of advanced antibody therapies, and surge in the geriatric population are the key factors driving the growth of the market. However, the high cost involved in new drug development coupled with the threat of failure and adverse effects associated with lung cancer antibody therapies is expected to restrain the growth of the market. Conversely, the high potential of emerging economies and the higher number of potential drugs in the pipeline are expected to provide new opportunities for market players in the future.
Our report provides a comprehensive analysis of globally approved lung cancer antibody therapeutics along with their commercial information including patent, price, dosage, and sales analysis. On the basis of drug type, the market is segmented into immune checkpoint inhibitors, monoclonal antibodies, and bispecific antibodies. Apart from this, the report also provides an in-depth analysis of ongoing clinical trials in the market. Some of the major companies mentioned in the report include AstraZeneca, Eli Lilly, Amgen, Pfizer, Roche, Innovent, Bristol Myers Squibb, and others.
At present, various therapeutic antibodies and immune checkpoint inhibitors have gained approval for the management of lung cancer. Immune checkpoint inhibitor therapy targeting the cytotoxic T-lymphocyte-associated antigen (CTLA-4) and programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) pathway have gained entry into the market. In addition to this, monoclonal antibodies including Cyramza, Avastin, and Portaza have also been approved for the management of various subtypes of lung cancer. Recently in 2021, a novel bispecific antibody Rybrevant (Amivantamab) was granted approval by US FDA. Rybrevant is an EGF and MET-directed bispecific antibody, developed by Janssen Pharmaceutical which is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EFGR) exon 20 insertion mutations. Clinical trials have demonstrated that the novel drug has shown enhanced efficacy in comparison to previously approved MET and EFGR inhibitors.
The huge clinical success of antibody therapeutics in the management of lung cancer has gained considerable momentum in the global market. In recent times, more enhance counterparts; trispecific antibodies which have the ability to bind to three different antigens simultaneously have also entered clinical development. HPN328 developed by Harpoon Therapeutics is TriTAC that binds to human and non-human primate DLL3, CD3ε, and albumin with similar affinities. US FDA has granted orphan drug designation for HPN328 for the treatment of small-cell lung cancer (SCLC). A Phase 1/2 clinical trial is currently ongoing for HPN328 in the SCLC patient population.
The global lung cancer antibody therapeutics market is highly consolidated with several key players investing in research and development. Several pharmaceutical giants have also adopted strategic alliances including partnerships, joint ventures, or collaborations to evaluate novel antibody therapeutics as monotherapy or in combinational therapy. Recently, Akeso has entered into collaboration with Shenzhen Chipscreen Biosciences to evaluate the combination of PD-1/CTLA-4 bi-specific antibody Cadonilimab in combination with Chiauranib for the treatment of first-line platinum-based chemotherapy in combination with PD-L1 inhibitor treatment regimen for extensive-stage small cell lung cancer (ES-SCLC).
As per our report findings, the global lung cancer antibody therapeutics market is expected to surpass US$ 10 Billion by 2028. The rise in the incidence of various lung cancer conditions, increase in popularity of advanced antibody therapies, and surge in the geriatric population are the key factors driving the growth of the market. However, the high cost involved in new drug development coupled with the threat of failure and adverse effects associated with lung cancer antibody therapies is expected to restrain the growth of the market. Conversely, the high potential of emerging economies and the higher number of potential drugs in the pipeline are expected to provide new opportunities for market players in the future.
Our report provides a comprehensive analysis of globally approved lung cancer antibody therapeutics along with their commercial information including patent, price, dosage, and sales analysis. On the basis of drug type, the market is segmented into immune checkpoint inhibitors, monoclonal antibodies, and bispecific antibodies. Apart from this, the report also provides an in-depth analysis of ongoing clinical trials in the market. Some of the major companies mentioned in the report include AstraZeneca, Eli Lilly, Amgen, Pfizer, Roche, Innovent, Bristol Myers Squibb, and others.
Global Lung Cancer Antibodies Market, Drug Sales & Clinical Trials Insight 2028 Report Highlights:
- Lung Cancer Antibodies Market Global & Regional Outlook
- Global Lung Cancer Antibodies Market Opportunity > USD 10 Billion
- Global & Regional Sales Analysis On 11 Antibodies
- Lung Cancer Immune Checkpoint Inhibitors, Monoclonal Antibodies, Bispecific Antibodies Insight
- Pricing, Dosage, Patent Insight On Approved Lung Cancer Antibodies
- Comprehensive Insight On More Than 200 Lung Cancer Antibodies in Clinical Trials
- Lung Cancer Antibodies in Clinical Trials Insight By Phase, Company, Orphan Designation
Table of Contents
1. Research Methodology2. Global Lung Cancer Antibodies Market Overview
2.1 Current Market Scenario
2.2 Regional Market Analysis
2.3 Future Market Opportunity
3. Global Lung Cancer Antibodies Clinical Trials Overview
3.1 By Company
3.2 By Country
3.3 By Phase
3.4 By Patient Segment
4. Lung Cancer Immune Checkpoint Inhibitors Insight
4.1 Overview
4.2 Drugs Availability, Patent, Price & Dosage Analysis
5. Lung Cancer Monoclonal Antibodies Insight
5.1 Overview
5.2 Drugs Availability, Patent, Price & Dosage Analysis
6. Lung Cancer Bispecific Antibodies Insight
6.1 Overview
6.2 Drugs Availability, Patent, Price & Dosage Analysis
7. Lung Cancer Monoclonal Antibodies - Global & Regional Sales Analysis
7.1 Opdivo
7.2 Keytruda
7.3 Yervoy
7.4 Imfinzi
7.5 Jemperli
7.6 Libtayo
7.7 Tecentriq
7.8 Avastin
7.9 Mvasi
7.10 Zirabev
7.11 Cyramza
8. Global Lung Cancer Antibodies Clinical Pipeline by Company, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase-I
8.5 Phase-I/Ii
8.6 Phase-Ii
8.7 Phase-Ii/Iii
8.8 Phase-Iii
8.9 Preregistration
8.10 Registered
9. Marketed Lung Cancer Antibodies Clinical, Patent & Orphan Designation Insight
10. Competitive Landscape
10.1 Abbvie
10.2 Amgen
10.3 Astrazeneca
10.4 Beigene
10.5 Bristol Myers Squibb
10.6 Eli Lilly
10.7 GlaxoSmithKline
10.8 Innovent
10.9 Janssen Pharmaceuticals
10.10 Merck
10.11 Pfizer
10.12 Roche
10.13 Samsung Bio10.8 Innovent
List of Figures
Figure 2-1: Global - Lung Cancer Incidences & Deaths (Million), 2020 & 2030
Figure 2-2: Global - Lung Cancer Antibodies Therapeutics Market Size (US$ Billion),2018 - 2021
Figure 2-3: Global - Lung Cancer Antibodies Therapeutics Market Size by Region(US$ Billion), 2021
Figure 2-4: Global - Lung Cancer Antibodies Therapeutics Market Size by Region(%), 2021
Figure 2-5: Global - Lung Cancer Antibodies Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-6: US - Lung Cancer Antibodies Therapeutics Market Size (US$ Billion),2022 - 2028
Figure 2-7: Europe - Lung Cancer Antibodies Therapeutics Market Size (US$ Billion),2022 - 2028
Figure 2-8: China - Lung Cancer Antibodies Therapeutics Market Size (US$ Billion),2022 - 2028
Figure 2-9: Japan - Lung Cancer Antibodies Therapeutics Market Size (US$ Billion),2022 - 2028
Figure 3-1: Global - Lung Cancer Antibodies in Clinical Trials by Company, 2022 till2028
Figure 3-2: Global - Lung Cancer Antibodies in Clinical Trials by Company, 2022 till2028
Figure 3-3: Global - Lung Cancer Antibodies in Clinical Trials by Phase, 2022 till2028
Figure 3-4: Global - Lung Cancer Antibodies in Clinical Trials by Patient Segment,2022 till 2028
Figure 4-1: Opdivo - Approval Year by Region
Figure 4-2: Opdivo - FDA Approval by Indication
Figure 4-3: Opdivo - Patent Expiration Year by Region
Figure 4-4: US - Price for 4ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-5: US - Price for 10 ml Supply & Price Per ml of Opdivo 10mg/ml intravenous Injection (US$), May’2022
Figure 4-6: US - Price for 12 ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-7: US - Price for 24 ml Supply & Price Per ml of Opdivo 10mg/ml intravenous Injection (US$), May’2022
Figure 4-8: UK - Price for 4 ml Supply & Price Per ml of Opdivo 10mg/ml intravenous Injection (GBP/US$), May’2022
Figure 4-9: UK - Price for 10ml Supply & Price Per ml of Opdivo 10mg/ml intravenous Injection (GBP/US$), May’2022
Figure 4-10: UK - Price for 24ml Supply & Price Per ml of Opdivo 10mg/ml intravenous Injection (GBP/US$), May’2022
Figure 4-11: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), May’2022
Figure 4-12: Keytruda - Approval Year by Region
Figure 4-13: Keytruda - FDA Approval Year by Indication
Figure 4-14: Keytruda - Patent Expiration Year by Region
Figure 4-15: US - Price for 4ml, 8ml Supply & Price Per ml of Keytruda IntravenousInjection (US$), May’2022
Figure 4-16: UK - Price for 4ml & Price Per ml of Keytruda 100mg IntravenousInjection (GBP/US$), May’2022
Figure 4-17: Yervoy - Approval Year by Region
Figure 4-18: Yervoy - FDA Approval Year by Indication
Figure 4-19: Yervoy - US & Europe Exclusivity Expiration Year
Figure 4-20: US - Price for 10ml Supply & Price Per ml of Yervoy 5mg/ml intravenous Injection (US$), May’2022
Figure 4-21: US - Price for 40ml Supply & Price Per ml 5mg/ml Yervoy IntravenousInjection (US$), May’2022
Figure 4-22: UK - Price for 10ml & Price Per ml of Yervoy 50mg IntravenousInjection (GBP/US$), May’2022
Figure 4-23: UK - Price for 40ml & Price Per ml of Yervoy 200mg IntravenousInjection (GBP/US$), May’2022
Figure 4-24: Imfinzi - FDA Approval Year by Indication
Figure 4-25: Imfinzi - Approval Year by Region
Figure 4-26: Imfinzi - FDA Approval & Patent Expiration Year
Figure 4-27: US- Price for a Supply of 2.4ml & Price Per ml of Imfinzi Solution for Injection (US$), May’2022
Figure 4-28: US - Price for a Supply of 10 ml & Price Per ml of Imfinzi Solution for Injection (US$), May’2022
Figure 4-29: UK- Price for a Supply of 2.4ml & Price Per ml of Imfinzi Solution for injection (GBP/US$), May’2022
Figure 4-30: UK- Price for a Supply of 10ml & Price Per ml of Imfinzi Solution for injection (GBP/US$), May’2022
Figure 4-31: Imfinzi - Average Cost of Single Treatment Cycle & Full Treatment of SCLC (US$), May’2022
Figure 4-32: US- Price for a Supply of 10ml & Price Per ml of Jemperli Solution for injection (US$), May’2022
Figure 4-33: UK- Price for a Supply of 10ml & Price Per ml of Jemperli Solution for Injection (GBP/US$), May’2022
Figure 4-34: Jemperli - Average Dose of Initial 4 Cycles & Subsequent Cycles (mg)
Figure 4-35: Jemperli - Average Cost of Initial 4 Cycles & Subsequent Cycles (US$),May’2022
Figure 4-36: Libtayo - Approval Year by Region
Figure 4-37: Libtayo - FDA Approval Year by Indication
Figure 4-38: US- Price for a Supply of 7ml & Price Per ml of Libtayo Solution for injection (US$), May’2022
Figure 4-39: UK- Price for a Supply of 7ml & Price Per ml of Libtayo Solution for injection (GBP/US$), May’2022
Figure 4-40: Libtayo - Cost of Single Treatment Cycle & Annual Treatment Cost(US$), May’2022
Figure 4-41: Tecentriq - Approval Year by Region
Figure 4-42: Tecentriq - FDA Approval Year by Indication
Figure 4-43: US- Price for 14ml Supply & Price Per ml of Tecentriq 840mg/14mlIntravenous Injection (US$), May’2022
Figure 4-44: US - Price for 20ml Supply & Price Per ml of Tecentriq 1200mg/20mlIntravenous Injection (US$), May’2022
Figure 4-45: UK- Price for a Supply of 20ml & Price Per ml of Tecentriq Solution for injection (GBP/US$), May’2022
Figure 4-46: UK- Price for a Supply of 14ml & Price Per ml of Tecentriq Solution for injection (GBP/US$), May’2022
Figure 4-47: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 840mg/2 Week Dose (US$), May’2022
Figure 4-48: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1200mg/3 Week Dose (US$), May’2022
Figure 4-49: Tecentriq - Average Cost of Single Treatment Cycle & AnnualTreatment using 1680mg/4 Week Dose (US$), May’2022
Figure 4-50: Tyvyt - NMPA Approval by Indication
Figure 4-51: Tislelizumab - NMPA Approval by Indication
Figure 5-1: Avastin - FDA Approval Year by Indication
Figure 5-2: Avastin - Approval Year by Region
Figure 5-3: US- Price for a Supply of 10 & Price for Single 4ml Avastin Solution for injection (US$), May’2022
Figure 5-4: US - Price for a Supply of 10 & Price for Single 16ml Avastin Solution for Injection (US$), May’2022
Figure 5-5: UK- Price for a Supply of 4ml & Price Per ml of Avastin Solution for injection (GBP/US$), May’2022
Figure 5-6: UK- Price for a Supply of 16ml & Price Per ml of Avastin Solution for injection (GBP/US$), May’2022
Figure 5-7: Avastin - Cost of Single Treatment Cycle & Annual Treatment Cost for SCLC (US$), May’2022
Figure 5-8: Mvasi - Approval Year by Region
Figure 5-9: Mvasi - Price for 4ml Supply & Price Per ml of Intravenous Solution(US$), May’2022
Figure 5-10: Mvasi - Price for 16 ml Supply & Price Per Unit of Intravenous Solution(US$), May’2022
Figure 5-11: Mvasi - Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), May’2022
Figure 5-12: US- Price for a Supply of 4ml & Price Per ml of Zirabev Solution forInjection (US$), May’2022
Figure 5-13: US- Price for a Supply of 16ml & Price Per ml of Zirabev Solution forInjection (US$), May’2022
Figure 5-14: UK- Price for a Supply of 16ml, 4ml & Price Per ml of Zirabev Solutionfor Injection (GBP/US$), May’2022
Figure 5-15: Zirabev - Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC (US$), May’2022
Figure 5-16: UK- Price for a Supply of 4ml & Price Per ml of Aybintio Solution for Injection (GBP/US$), May’2022
Figure 5-17: UK- Price for a Supply of 16ml & Price Per ml of Aybintio Solution for Injection (GBP/US$), May’2022
Figure 5-18: Cyramza - Approval Year by Region
Figure 5-19: US - Cyramza FDA Approval History by Indication
Figure 5-20: US - Cyramza Patent Approval & Expiration Year
Figure 5-21: Cyramza - Patent Exclusivity by Region
Figure 5-22: US - Cost of 10ml & Per unit Price of Cyramza 10mg/ml IntravenousSolution (US$), May’2022
Figure 5-23: US - Cost of 50ml & Per unit Price of Cyramza 10mg/ml IntravenousSolution (US$), May’2022
Figure 5-24: UK- Price for a Supply of 10ml & Price Per ml of Cyramza Solution for Injection (GBP/US$), May’2022
Figure 5-25: UK- Price for a Supply of 50ml & Price Per ml of Cyramza Solution forInjection (GBP/US$), May’2022
Figure 5-26: Cyramza - Cost of Single Treatment Cycle & Annual Treatment Cost forNSCLC (US$), May’2022
Figure 5-27: US - Necitumumab FDA Approval & Patent Exclusivity Year
Figure 5-28: Portrazza - Price for 50ml Supply & Price per unit of 16mg IntravenousSolution (US$), May’2022
Figure 5-29: Portrazza - Minimum Dose & Maximum Dose (in mg)
Figure 6-1: US- Price for 7ml Supply & Price per Unit of Rybrevant 50mg/mlIntravenous Solution (US$), May’2022
Figure 6-2: UK- Price for a 7ml Supply & Price per Unit of Rybrevant 50mg/mlIntravenous Solution (GBP/US$), May’2022
Figure 6-3: Rybrevant - Recommended Dose Per Cycle by Body Weight (mg)
Figure 6-4: Rybrevant - Dose Reduction in Patients with Weight Less Than 80Kg(mg)
Figure 6-5: Rybrevant - Dose Reduction in Patients with Weight More Than 80Kg(mg)
Figure 7-1: Global - Opdivo Sales Value by Region (US$ Million), Q1’2022
Figure 7-2: Global - Opdivo Sales Value by Region (%), Q1’2022
Figure 7-3: Global - Opdivo Sales (US$ Million), 2018-2021
Figure 7-4: US - Opdivo Sales (US$ Million), 2018-2021
Figure 7-5: Global - Opdivo Sales by Region (US$ Million), 2021
Figure 7-6: Global - Opdivo Sales by Region (%), 2021
Figure 7-7: Global - Opdivo Quatery Sales (US$ Million), 2021
Figure 7-8: US - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 7-9: Global - Opdivo Quarterly Sales (US$ Million), 2020
Figure 7-10: US - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 7-11: Global - Keytruda Sales (US$ Million), Q1’2021 & Q1’2022
Figure 7-12: Global - Keytruda Sales (US$ Billion), 2018 - 2021
Figure 7-13: Global - Keytruda Quarterly Sales (US$ Billion), 2021
Figure 7-14: Global - Keytruda Quarterly Sales (US$ Billion), 2020
Figure 7-15: Global - Yervoy Sales by Region (US$ Million), Q1’2022
Figure 7-16: Global - Yervoy Sales by Region (%), Q1’2022
Figure 7-17: Global - Yervoy Sales (US$ Million), 2018 - 2021
Figure 7-18: US - Yervoy Sales (US$ Million), 2018 - 2021
Figure 7-19: Yervoy - Sales by Region (US$ Million), 2021
Figure 7-20: Yervoy - Sales by Region (US$ Million), 2021
Figure 7-21: Global - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 7-22: US - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 7-23: Global - Yervoy Quarterly Sales Value (US$ Million), 2020
Figure 7-24: US - Yervoy Quarterly Sales Value (US$ Million), 2020
Figure 7-25: Imfinzi -Sales by Region (US$ Million), Q1’2022
Figure 7-26: Imfinzi -Sales by Region (US$ Million), Q1’2022
Figure 7-27: Global - Imfinzi Sales (US$ Million), 2019 - 2021
Figure 7-28: US - Imfinzi Sales (US$ Million), 2019 - 2021
Figure 7-29: Europe - Imfinzi Sales (US$ Million), 2019 - 2021
Figure 7-30: Imfinzi - Sales by Region (US$ Million), 2021
Figure 7-31: Imfinzi - Sales by Region (%), 2021
Figure 7-32: Global - Imfinzi Quarterly Sales (US$ Million), 2021
Figure 7-33: US - Imfinzi Quarterly Sales (US$ Million), 2021
Figure 7-34: Global - Imfinzi Quarterly Sales (US$ Million), 2020
Figure 7-35: US - Imfinzi Quarterly Sales (US$ Million), 2020
Figure 7 36: Global - Jemperli Sales by Region (US$/GBP Million), Q1’2022
Figure 7 37: Global - Jemperli Sales by Region (US$/GBP Million), 2021
Figure 7-38: Global - Jemperli Sales by Region (%), 2021
Figure 7-39: US - Jemperli Sales (US$/GBP Million), Q3 & Q4’2021
Figure 7-40: Libtayo -Sales by Region (US$ Million), Q1’2022
Figure 7-41: Libtayo -Sales by Region (%), Q1’2022
Figure 7-42: Global - Libtayo Sales (US$ Million), 2018 - 2021
Figure 7-43: US - Libtayo Sales (US$ Million), 2018 - 2021
Figure 7-44: Libtayo - Sales by Region (US$ Million), 2021
Figure 7-45: Libtayo - Sales by Region (%), 2021
Figure 7-46: Global - Libtayo Quarterly Sales (US$ Million), 2021
Figure 7-47: US - Libtayo Quarterly Sales (US$ Million), 2021
Figure 7-48: Global - Libtayo Quarterly Sales (US$ Million), 2020
Figure 7-49: US - Libtayo Quarterly Sales (US$ Million), 2020
Figure 7-50: Tecentriq -Sales by Region (US$/CHF Million), Q1’2022
Figure 7-51: Tecentriq -Sales by Region (%),Q1’2022
Figure 7-52: Global - Tecentriq Annul Sales (US$/CHF Million), 2019 - 2021
Figure 7-53: US - Tecentriq Sales (US$/CHF Million), 2019 - 2021
Figure 7-54: Europe - Tecentriq Sales (US$/CHF Million), 2019 - 2021
Figure 7-55: Japan - Tecentriq Sales (US$/CHF Million), 2019 - 2021
Figure 7-56: ROW - Tecentriq Sales (US$/CHF Million), 2019 - 2021
Figure 7-57: Tecentriq - Sales by Region (US$/CHF Million), 2021
Figure 7-58: Tecentriq - Sales by Region (%), 2021
Figure 7-59: Global - Tecentriq Quarterly Sales (US$ Billion), 2021
Figure 7-60: US - Tecentriq Quarterly Sales (US$ Billion), 2021
Figure 7-61: US - Tecentriq Quarterly Sales (US$ Million), 2020
Figure 7-62: Avastin -Sales by Region (US$/CHF Million), Q1’2022
Figure 7-63: Avastin -Salesby Region (%), Q1’2022
Figure 7-64: Global - Avastin Sales (US$/CHF Million), 2019 - 2021
Figure 7-65: US - Avastin Sales (US$/CHF Million), 2019 - 2021
Figure 7-66: Europe - Avastin Sales (US$/CHF Million), 2019 - 2021
Figure 7-67: Japan - Avastin Annual Sales(US$/CHF Million), 2019 - 2021
Figure 7-68: ROW - Avastin Sales (US$/CHF Million), 2019 - 2021
Figure 7-69: Avastin - Sales by Region (US$/CHF Million), 2021
Figure 7-70: Avastin - Sales by Region (%), 2021
Figure 7-71: Global - Avastin Quarterly Sales (US$/CHF Million), 2021
Figure 7-72: US - Avastin Quarterly Sales (US$/CHF Million), 2021
Figure 7-73: Mvasi -Sales by Region (US$ Million), Q1’2022
Figure 7-74: Mvasi -Salesby Region (%), Q1’2022
Figure 7-75: Global - Mvasi Sales (US$ Million), 2019 - 2021
Figure 7-76: US - Mvasi Sales (US$ Million), 2019 - 2021
Figure 7-77: ROW - Mvasi Sales (US$ Million), 2019 - 2021
Figure 7-78: Mvasi -Sales by Region (US$ Million), 2021
Figure 7-79: Mvasi -Sales by Region (%), 2021
Figure 7-80: Global - Mvasi Quarterly Sales (US$ Million), 2021
Figure 7-81: US - Mvasi Quarterly Sales (US$ Million), 2021
Figure 7-82: Global - Mvasi Quarterly Sales (US$ Million), 2020
Figure 7-83: Zirabev -Sales by Region (US$ Million), Q1’2022
Figure 7-84: Zirabev -Sales by Region (%),Q1’2022
Figure 7-85: Global - Zirabev Sales (US$ Million), 2020 & 2021
Figure 7-86: US - Zirabev Sales (US$ Million), 2020 & 2021
Figure 7-87: Zirabev -Sales by Region (US$ Million), 2021
Figure 7-88: Zirabev -Sales by Region (%), 2021
Figure 7-89: Global - Zirabev Quarterly Sales (US$ Million), 2021
Figure 7-90: US - Zirabev Quarterly Sales (US$ Million), 2021
Figure 7-91: US - Zirabev Quarterly Sales (US$ Million), 2020
Figure 7-92: Global - Cyramza Sales (US$ Million), Q1’2021 & Q1’2022
Figure 7-93: Global - Cyramza Sales (US$ Million), 2017 - 2021
Figure 7-94: US - Cyramza Sales (US$ Million), 2017 - 2021
Figure 7-95: Global - Cyramza Sales by Region (US$ Million), 2021
Figure 7-96: Global - Cyramza Sales (%) by Region, 2021
Figure 7-97: Global - Cyramza Sales by Region (US$ Million), 2020
Figure 7-98: Global - Cyramza Sales by Region (%), 2020
Figure 7-99: Global - Cyramza Quarterly Sales (US$ Million), 2021 & 2020
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Amgen
- AstraZeneca
- BeiGene
- Bristol Myers Squibb
- Eli Lilly
- GlaxoSmithKline
- Innovent
- Janssen Pharmaceuticals
- Merck
- PfizerRoche
- Samsung Bio
